189 related articles for article (PubMed ID: 32712254)
1. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
Choi BO; Choi IB; Jang HS; Kang YN; Jang JS; Bae SH; Yoon SK; Chai GY; Kang KM
BMC Cancer; 2008 Nov; 8():351. PubMed ID: 19038025
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y; Kimura T; Aikata H; Kobayashi T; Fukuhara T; Masaki K; Nakahara T; Naeshiro N; Ono A; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Ishikawa M; Kakizawa H; Kenjo M; Takahashi S; Awai K; Nagata Y; Chayama K
J Gastroenterol Hepatol; 2013 Mar; 28(3):530-6. PubMed ID: 23216217
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.
Kang JK; Kim MS; Cho CK; Yang KM; Yoo HJ; Kim JH; Bae SH; Jung DH; Kim KB; Lee DH; Han CJ; Kim J; Park SC; Kim YH
Cancer; 2012 Nov; 118(21):5424-31. PubMed ID: 22570179
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y; Kimura T; Aikata H; Nakahara T; Naeshiro N; Tanaka M; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Waki K; Ishikawa M; Kakizawa H; Kenjo M; Awai K; Nagata Y; Chayama K
Hepatogastroenterology; 2014; 61(129):31-6. PubMed ID: 24895789
[TBL] [Abstract][Full Text] [Related]
8. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
[TBL] [Abstract][Full Text] [Related]
9. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.
Pinato DJ; D'Alessio A; Fulgenzi CAM; Schlaak AE; Celsa C; Killmer S; Blanco JM; Ward C; Stikas CV; Openshaw MR; Acuti N; Nteliopoulos G; Balcells C; Keun HC; Goldin RD; Ross PJ; Cortellini A; Thomas R; Young AM; Danckert N; Tait P; Marchesi JR; Bengsch B; Sharma R
Clin Cancer Res; 2024 Jun; 30(11):2433-2443. PubMed ID: 38578610
[TBL] [Abstract][Full Text] [Related]
10. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Dumago MP; Agas RAF; Jainar CJE; Yap ET; Co LBA; Ortin TTS
J Gastrointest Cancer; 2023 Dec; 54(4):1058-1070. PubMed ID: 37306936
[TBL] [Abstract][Full Text] [Related]
12. Brachytherapy with Iodine-125 seeds for treatment of portal vein-branch tumor thrombus in patients with hepatocellular carcinoma.
Hong D; Zhou Y; Wan X; Su H; Shao H
BMC Cancer; 2021 Sep; 21(1):1020. PubMed ID: 34521375
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
[TBL] [Abstract][Full Text] [Related]
14. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.
Pokuri VK; Tomaszewski GM; Ait-Oudhia S; Groman A; Khushalani NI; Lugade AA; Thanavala Y; Ashton EA; Grande C; Fetterly GJ; Iyer R
Am J Clin Oncol; 2018 Apr; 41(4):332-338. PubMed ID: 27014931
[TBL] [Abstract][Full Text] [Related]
16. 131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.
Ma J; Wang JH
Asian Pac J Cancer Prev; 2015; 16(17):7441-7. PubMed ID: 26625741
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
Tong H; Wei B; Chen S; Xie YM; Zhang MG; Zhang LH; Huang ZY; Tang CW
Oncotarget; 2017 Jul; 8(29):48303-48312. PubMed ID: 28430638
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm.
Jacob R; Turley F; Redden DT; Saddekni S; Aal AK; Keene K; Yang E; Zarzour J; Bolus D; Smith JK; Gray S; White J; Eckhoff DE; DuBay DA
HPB (Oxford); 2015 Feb; 17(2):140-9. PubMed ID: 25186290
[TBL] [Abstract][Full Text] [Related]
19. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
20. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis.
Bush DA; Smith JC; Slater JD; Volk ML; Reeves ME; Cheng J; Grove R; de Vera ME
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):477-482. PubMed ID: 27084661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
